Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Twist Bioscience Corp (NASDAQ: TWST) was $35.59 for the day, down -6.76% from the previous closing price of $38.17. In other words, the price has decreased by -$6.76 from its previous closing price. On the day, 1.06 million shares were traded. TWST stock price reached its highest trading level at $37.76 during the session, while it also had its lowest trading level at $35.44.
Ratios:
Our analysis of TWST’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.51. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $60.
On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.
Goldman Upgraded its Neutral to Buy on January 17, 2024, whereas the target price for the stock was revised from $25 to $45.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 02 ’25 when Cho Dennis sold 125 shares for $36.19 per share. The transaction valued at 4,524 led to the insider holds 104,612 shares of the business.
Finn Patrick John sold 209 shares of TWST for $7,564 on Jul 02 ’25. The President and COO now owns 240,574 shares after completing the transaction at $36.19 per share. On Jul 02 ’25, another insider, Leproust Emily M., who serves as the Chief Executive Officer of the company, sold 476 shares for $36.19 each. As a result, the insider received 17,228 and left with 645,306 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 2132413952 and an Enterprise Value of 2027465856. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.13 while its Price-to-Book (P/B) ratio in mrq is 4.84. Its current Enterprise Value per Revenue stands at 5.831 whereas that against EBITDA is -15.465.
Stock Price History:
The Beta on a monthly basis for TWST is 2.38, which has changed by -0.2952475 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $60.90, while it has fallen to a 52-week low of $27.12. The 50-Day Moving Average of the stock is 5.43%, while the 200-Day Moving Average is calculated to be -14.75%.
Shares Statistics:
TWST traded an average of 1.21M shares per day over the past three months and 960800 shares per day over the past ten days. A total of 59.86M shares are outstanding, with a floating share count of 56.69M. Insiders hold about 5.39% of the company’s shares, while institutions hold 110.05% stake in the company. Shares short for TWST as of 1749772800 were 10308992 with a Short Ratio of 8.51, compared to 1747267200 on 10616307. Therefore, it implies a Short% of Shares Outstanding of 10308992 and a Short% of Float of 19.43.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Twist Bioscience Corp (TWST) is currently attracting attention from 3.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.43 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$2.14 and -$2.32 for the fiscal current year, implying an average EPS of -$2.23. EPS for the following year is -$1.81, with 4.0 analysts recommending between -$1.34 and -$2.45.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $96.39M to a low estimate of $94M. As of the current estimate, Twist Bioscience Corp’s year-ago sales were $81.46MFor the next quarter, 9 analysts are estimating revenue of $99.17M. There is a high estimate of $100.1M for the next quarter, whereas the lowest estimate is $97.34M.
A total of 10 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $377.67M, while the lowest revenue estimate was $372.75M, resulting in an average revenue estimate of $375.89M. In the same quarter a year ago, actual revenue was $312.97MBased on 10 analysts’ estimates, the company’s revenue will be $441.59M in the next fiscal year. The high estimate is $448M and the low estimate is $427M.
